Iambic Therapeutics Prices IPO at $16.00 Per Share

Key Facts

Iambic Therapeutics announced the pricing of its initial public offering of 9,375,000 shares at $16.00 per share. Business Wire reported that the company expects to raise gross proceeds of approximately $150 million from the offering.

The company intends to use the raised capital to advance its clinical-stage life sciences and technology platform, which utilizes AI for novel medicine discovery. The listing on the Nasdaq provides a new benchmark for the AI-driven drug discovery sector.